MedTrace Logo

Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients

NCT00837967 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2012-08-29

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler® 160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on top of Symbicort® Turbuhaler® 160/4.5 μg 1 inhalation twice a day (bid) in adult asthma patients.

Conditions

Interventions

DRUG

Symbicort Turbuhaler

160/4.5μg for 3 days

DRUG

Terbutaline Turbuhaler

0.4 mg for 3 days

Sponsors & Collaborators

Principal Investigators

  • Tomas Andersson, MD · AstraZeneca R&D Lund

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837967 on ClinicalTrials.gov